Current opinion on optimal treatment for colorectal cancer

References

• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J. Clin. Oncol. 23(36), 9441–9442 (2005).
   PubMed Web of Science ®Google Scholar
• Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), 2020–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Yothers GA, Allegra CJ, O’Connell MJ et al. The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3–7 June 2011 (Abstract 3507).
   Google Scholar
• Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219–3226 (2010).
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19), 3109–3116 (2009).
   PubMed Web of Science ®Google Scholar
• Romanus D, Weiser MR, Skibber JM et al. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J. Natl Compr. Canc. Netw. 7(8), 895–904 (2009).
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Mounedji-Boudiaf L et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol. 29(28), 3768–3774 (2011).
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol. 29(11), 1465–1471 (2011).
   PubMed Web of Science ®Google Scholar
• Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann. Oncol. 23(5), 1190–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27(19), 3117–3125 (2009).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ et al. Bevacizumab in stage II–III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31(3), 359–364 (2013).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet Oncol. 13(12), 1225–1233 (2012).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J. Clin. Oncol. 29(1), 1–4 (2011).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8(4), 210–221 (2011).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307(13), 1383–1393 (2012).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J. Clin. Oncol. 30(31), 3827–3833 (2012).
   PubMed Web of Science ®Google Scholar
• Rödel C, Liersch T, Becker H et al.; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised Phase 3 trial. Lancet Oncol. 13(7), 679–687 (2012).
   PubMed Web of Science ®Google Scholar
• Gérard JP, Azria D, Gourgou-Bourgade S et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. 30(36), 4558–4565 (2012).
   PubMed Web of Science ®Google Scholar
• Chen CF, Huang MY, Huang CJ et al. A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. Int. J. Colorectal Dis. 27(6), 727–736 (2012).
   Google Scholar
• Midgley RS, McConkey CC, Johnstone EC et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol. 28(30), 4575–4580 (2010).
   Google Scholar
• Lundberg GD. Aspirin helps prevent recurring colorectal adenomas – folic acid does not. Medscape J. Med. 10(3), 69 (2008).
   Google Scholar
• Ali R, Toh HC, Chia WK; ASCOLT Trial Investigators. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer – the ASCOLT study: study protocol for a randomized controlled trial. Trials 12, 261 (2011).
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367(17), 1596–1606 (2012).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B et al.; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617), 1007–1016 (2008).
   PubMed Web of Science ®Google Scholar
• Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann. Surg. Oncol. 16(9), 2385–2390 (2009).
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg. 240(4), 644–657; discussion 657 (2004).
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1), 38–50 (2007).
   PubMed Web of Science ®Google Scholar
• Seymour MT, Maughan TS, Ledermann JA et al.; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582), 143–152 (2007).
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G et al.; Gruppo Oncologico Dell’Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol. 23(22), 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum – applying current evidence to clinical practice. Cancer Treat. Rev. 38(5), 397–406 (2012).
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I et al.; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670–1676 (2007).
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer 94(6), 798–805 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Puthillath A, Patel A, Fakih MG. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco. Targets. Ther. 2, 1–15 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Karapetis CS, Gibbs P et al. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit. Rev. Oncol. Hematol. 85(2), 121–135 (2013).
   Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706–4713 (2010).
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812–1820 (2010).
   PubMed Web of Science ®Google Scholar
• Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30(29), 3570–3577 (2012).
   PubMed Web of Science ®Google Scholar
• Guerrero S, Casanova I, Farré L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 60(23), 6750–6756 (2000).
   PubMed Web of Science ®Google Scholar
• Peeters M. KRAS mutations in colorectal trials using panitumumab. Ann. Oncol. (2011).
   Google Scholar
• De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12(6), 594–603 (2011).
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG et al.; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet 377(9783), 2103–2114 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30(15), 1755–1762 (2012).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697–4705 (2010).
   PubMed Web of Science ®Google Scholar
• Seymour MT, Brown SR, Richman S et al. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J. Clin. Oncol. 29, Abstract 3523 (2011).
   Google Scholar
• Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br. J. Cancer 100(2), 251–258 (2009).
   PubMed Web of Science ®Google Scholar
• Grothey A, Lenz HJ, Cats A et al. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J. Clin. Oncol. 30(15), 1735–1737 (2012).
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563–572 (2009).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672–680 (2009).
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6(8), 465–477 (2009).
   PubMed Web of Science ®Google Scholar
• Lise M, Da Pian PP, Nitti D, Pilati PL. Colorectal metastases to the liver: present results and future strategies. J. Surg. Oncol. Suppl. 2, 69–73 (1991).
   Google Scholar
• Bismuth H, Adam R, Navarro F, Castaing D, Engerran L, Abascal A. Re-resection for colorectal liver metastasis. Surg. Oncol. Clin. N. Am. 5(2), 353–364 (1996).
   PubMedGoogle Scholar
• Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8(4), 347–353 (2001).
   PubMed Web of Science ®Google Scholar
• Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16(8), 1311–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Leichman L. The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer. Surg. Oncol. Clin. N. Am. 16(3), 537–56, viii (2007).
   PubMedGoogle Scholar
• Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist 17(2), 201–211 (2012).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26(33), 5326–5334 (2008).
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 16(2), 125–131 (2010).
   PubMedGoogle Scholar
• Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48(10), 1466–1475 (2012).
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised Phase 2 trial. Lancet Oncol. 11(1), 38–47 (2010).
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135–142 (2007).
   PubMed Web of Science ®Google Scholar
• Ducreux M, Malka D, Mendiboure J et al.; Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, Phase 3 trial. Lancet Oncol. 12(11), 1032–1044 (2011).
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 28(19), 3191–3198 (2010).
   PubMed Web of Science ®Google Scholar
• Price TJ, Zannino D, Wilson K et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann. Oncol. 23(6), 1531–1536 (2012).
   PubMed Web of Science ®Google Scholar
• Price TJ, Townsend AR, Beeke C et al. ‘Watchful waiting’ for metastatic colorectal cancer, antediluvian or an option to be considered again? Asia. Pac. J. Clin. Oncol. 8(1), 10–13 (2012).
   PubMedGoogle Scholar
• Doroshow JH, Synold TW, Gandara D et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. 30(4 Suppl. 15), 14–19 (2003).
   PubMed Web of Science ®Google Scholar
• Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park, N.Y.) 19(8), 1057–1063; discussion 1063 (2005).
   PubMed Web of Science ®Google Scholar
• Ong SY, Clarke SJ, Bishop J, Dodds HM, Rivory LP. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer. Drugs 12(7), 619–625 (2001).
   PubMedGoogle Scholar
• Townsend AR, Bishnoi S, Broadbridge V et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am. J. Clin. Oncol. 36(1), 49–52 (2013).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol. 24(3), 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J. Clin. Oncol. 27(34), 5727–5733 (2009).
   PubMed Web of Science ®Google Scholar
• Labianca R, Sobrero A, Isa L et al.; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial. Ann. Oncol. 22(5), 1236–1242 (2011).
   PubMed Web of Science ®Google Scholar
• Neo EL, Beeke C, Price T et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J. Surg. 81(5), 352–357 (2011).
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 14(1), 29–37 (2013).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Siena S et al. Results of a Phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Presented at: 2012 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 19–21 January 2012 (Abstract LBA385).
   Google Scholar
• Yoshino T, Mizunuma N, Yamazaki K et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled Phase 2 trial. Lancet Oncol. 13(10), 993–1001 (2012).
   PubMed Web of Science ®Google Scholar
• Siu LL, Shapiro JD, Jonker DsJ et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J. Clin. Oncol. 30(Suppl. 4), Abstract 386 (2012).
   Google Scholar